Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2025	Dec. 31, 2024
Operating expenses:
Research and development	$ 14,348	$ 12,627	$ 27,497	$ 25,381
General and administrative	9,873	4,453	16,541	8,640
Total operating expenses	24,221	17,080	44,038	34,021
Operating loss	(24,221)	(17,080)	(44,038)	(34,021)
Non-operating income (expense):
Interest and other income, net	1,447	1,344	3,129	2,922
Income (loss) from change in fair value of embedded derivative liability		6	(15)	(9)
Total non-operating income, net	1,447	1,350	3,114	2,913
Net loss	(22,774)	(15,730)	(40,924)	(31,108)
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable debt securities	(2)	(225)	54	143
Comprehensive loss	$ (22,776)	$ (15,955)	$ (40,870)	$ (30,965)
Net loss per common share - basic (in dollars per share)	$ (0.22)	$ (0.22)	$ (0.4)	$ (0.45)
Net loss per common share - diluted (in dollars per share)	$ (0.22)	$ (0.22)	$ (0.4)	$ (0.45)
Weighted average number of common shares outstanding - basic (in shares)	103,687,064	69,940,319	103,554,855	69,838,235
Weighted average number of common shares outstanding - diluted (in shares)	103,687,064	69,940,319	103,554,855	69,838,235